VCAM1 is highly enriched in glioma stem cell-like cells, with 86.5% of SOX2+, 86.3% of CD133+, and 93.4% of Ki67+ cells co-expressing it in the 73C model. This dataset likely contains tabular data from experiments correlating VCAM1 expression with patient survival and mouse model outcomes, authored by Jiajing Dai and published on figshare in 2026. Selective deletion of astrocytic VCAM1 extended median survival from 52 to 66.5 days in a hippocampal GL261 model.
Use Cases
- Correlate VCAM1 expression levels with patient survival outcomes based on human glioma datasets mentioned in the description
- Analyze the functional impact of astrocytic VCAM1 ablation on tumor growth based on mouse model experiments
- Investigate the relationship between VCAM1 and glioma stem cell markers (SOX2, CD133, Ki67) based on co-expression percentages
- Evaluate VCAM1 as a therapeutic target based on its role in mediating tumor-TME interactions
Strengths
- Includes specific experimental results, such as co-expression percentages (86.5%, 86.3%, 93.4%) and survival extension (52 to 66.5 days)
- Integrates findings from both human clinical data and mouse models (syngeneic and primary)
- Published under an open CC-BY-4.0 license
Limitations
- Column-level documentation is absent; field semantics must be inferred after download
- Row count is unknown, which may limit suitability assessment
- The dataset is small (140.8 KB), indicating limited scope
Provenance
- Source
- figshare
- Collection Method
- Likely contains data from analysis of human glioma datasets and experiments using syngeneic and primary mouse glioma models.
- Freshness
- Last updated 2026-04-24 04:23:03; freshness should be verified